Proteon Therapeutics, Inc.
(NASDAQ GM: PRTO)
Attention investors who purchased shares of Proteon Therapeutics, Inc. before September 23, 2019:
Rigrodsky & Long is investigating potential claims against the board of directors of Proteon Therapeutics, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to merge with ArTara Therapeutics, Inc.
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (NASDAQ GM: PRTO) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to merge with ArTara Therapeutics, Inc. (“ArTara”). Under the terms of the agreement, shareholders of Proteon will own approximately 10% of the combined company, while ArTara security holders will own approximately 90%.
If you own common stock of Proteon and purchased any shares before September 23, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.